<DOC>
	<DOCNO>NCT01006057</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial evaluate NN1250 ( insulin degludec/insulin 454 ) concentration-time curve alter extent dose adjust subject impaired renal function compare dose subject normal renal function .</brief_summary>
	<brief_title>A Trial Investigating NN1250 Concentration-time Curve Subjects With Various Degrees Renal Impairment Subjects With Normal Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Subject normal renal function renal impairment ( mild , moderate , severe end stage renal disease ( ESRD ) require haemodialysis ) Body mass index maximum 40.0 kg/m^2 Subject disease condition Investigator feel would interfere trial except condition associate renal impairment group subject compromise renal function . Diabetes mellitus accept group patient renal impairment , subject normal renal function Subject donate blood plasma past month 500 mL within 3 month prior screen Significant history alcoholism drug/chemical abuse Not able willing refrain smoking inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>